US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU6479101A
(en)
*
|
2000-06-16 |
2002-01-02 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
CA2436595C
(en)
|
2000-12-08 |
2011-11-08 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
WO2002048192A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US7101843B2
(en)
*
|
2001-08-23 |
2006-09-05 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
NZ531788A
(en)
*
|
2001-10-18 |
2008-01-31 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2468700A1
(en)
*
|
2002-01-08 |
2003-07-17 |
Eli Lilly And Company |
Extended glucagon-like peptide-1 analogs
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
DE60331226D1
(de)
|
2002-05-24 |
2010-03-25 |
Medtronic Inc |
Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
CA2490409A1
(en)
*
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
EP1545595B1
(en)
*
|
2002-08-30 |
2010-07-07 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
AU2003283216A1
(en)
*
|
2002-12-03 |
2004-06-23 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
US7314859B2
(en)
|
2002-12-27 |
2008-01-01 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US20060223767A1
(en)
*
|
2003-01-10 |
2006-10-05 |
Haruo Hanawa |
Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy
|
WO2004069862A1
(ja)
*
|
2003-02-06 |
2004-08-19 |
Keio University |
ペプチド結合体
|
CN1832959A
(zh)
*
|
2003-03-19 |
2006-09-13 |
伊莱利利公司 |
聚乙二醇连接的glp-1化合物
|
BRPI0408978B8
(pt)
|
2003-04-08 |
2021-07-27 |
Novo Nordisk As |
processos para regenerar uma fase estacionária cromatográfica
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
US7259234B2
(en)
|
2003-05-15 |
2007-08-21 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
EP1641483B1
(en)
*
|
2003-06-12 |
2008-02-13 |
Eli Lilly And Company |
Fusion proteins
|
KR100758755B1
(ko)
*
|
2003-06-12 |
2007-09-14 |
일라이 릴리 앤드 캄파니 |
Glp-1 유사체 융합 단백질
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
CA2539253A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US8263084B2
(en)
*
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
US20090238838A1
(en)
*
|
2003-11-13 |
2009-09-24 |
Hanmi Pharm. Ind. Co. Ltd. |
Insulinotropic peptide conjugate using an immunoglobulin fc
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
KR20050047030A
(ko)
|
2003-11-13 |
2005-05-19 |
한미약품 주식회사 |
약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법
|
KR101135244B1
(ko)
*
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
AU2004290862B2
(en)
|
2003-11-20 |
2010-06-03 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
CA2550050A1
(en)
*
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel glp-1 analogues linked to albumin-like agents
|
US20060252693A1
(en)
*
|
2004-01-29 |
2006-11-09 |
Wolfgang Glaesner |
Glucagon-like peptide-1 analogs
|
CN1980687B
(zh)
*
|
2004-02-09 |
2015-05-13 |
人类基因科学公司 |
清蛋白融合蛋白
|
CN102816241B
(zh)
*
|
2004-02-09 |
2015-07-22 |
人类基因科学公司 |
清蛋白融合蛋白
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP2335716A3
(en)
|
2004-02-11 |
2011-10-19 |
Amylin Pharmaceuticals Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
EP2417980A1
(en)
*
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
KR20070004078A
(ko)
*
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
EP3404102B1
(en)
|
2004-04-21 |
2021-08-11 |
Alexion Pharmaceuticals, Inc. |
Bone delivery conjugates and method of using same to target proteins to bone
|
DK1751184T3
(da)
|
2004-05-13 |
2009-11-23 |
Lilly Co Eli |
FGF-21 fusionsproteiner
|
CN1950078A
(zh)
|
2004-06-11 |
2007-04-18 |
诺和诺德公司 |
使用glp-1激动剂抵抗药物诱发的肥胖
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
EP2330126B1
(en)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
CN101128487B
(zh)
*
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
EA200701362A1
(ru)
*
|
2004-12-22 |
2008-08-29 |
Сентокор, Инк. |
Агонисты glp-1, композиции, способы и применения
|
SI1831252T1
(sl)
*
|
2004-12-22 |
2009-12-31 |
Lilly Co Eli |
Formulacije analogov glp-1 fuzijskih proteinov
|
US20090016959A1
(en)
*
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
CN101128214A
(zh)
*
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
长效glp-1化合物
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
BRPI0520168A2
(pt)
*
|
2005-03-28 |
2009-04-22 |
Centocor Inc |
mimeticorpos de glp-1 humanos, composiÇÕes, mÉtodos e usos
|
ES2605380T3
(es)
*
|
2005-05-06 |
2017-03-14 |
Providence Health & Services - Oregon |
Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
|
WO2006124529A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Eli Lilly And Company |
Glp-1 pegylated compounds
|
EP1920061A4
(en)
*
|
2005-07-27 |
2009-05-13 |
Wang Qinghua |
GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
|
WO2007018619A2
(en)
*
|
2005-07-29 |
2007-02-15 |
Amprotein Corporation |
Chimeric therapeutic agents
|
EP1924293A4
(en)
*
|
2005-08-06 |
2008-12-24 |
Qinghua Wang |
COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
|
CA2617649A1
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
KR101399178B1
(ko)
*
|
2005-08-11 |
2014-06-18 |
아스트라제네카 파마수티컬스 엘피 |
선별가능한 특성을 갖는 하이브리드 폴리펩티드
|
DK1767545T3
(da)
|
2005-09-22 |
2010-03-15 |
Biocompatibles Uk Ltd |
GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
|
EP1942115A4
(en)
*
|
2005-10-26 |
2009-03-18 |
Chugai Pharmaceutical Co Ltd |
AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION
|
DK1965823T3
(en)
*
|
2005-11-04 |
2016-08-22 |
Glaxosmithkline Llc Corp Service Company |
Methods of administering hypoglycemics
|
CN1962695B
(zh)
*
|
2005-11-09 |
2011-08-31 |
浙江德清安平生物制药有限公司 |
类胰高血素肽-1融合蛋白及其制备和用途
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
WO2007063907A1
(ja)
*
|
2005-11-30 |
2007-06-07 |
Shionogi & Co., Ltd. |
ペプチド糖鎖付加体およびそれを有効成分とする医薬
|
JP5096363B2
(ja)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
Glp−1のポリマ複合体
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
CA2634034A1
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
KR20140091765A
(ko)
*
|
2006-01-12 |
2014-07-22 |
알렉시온 파마슈티칼스, 인코포레이티드 |
Ox-2/cd200에 대한 항체 및 이들의 용도
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
WO2007092252A2
(en)
|
2006-02-03 |
2007-08-16 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
CN101003574B
(zh)
*
|
2006-02-21 |
2010-12-15 |
大连帝恩生物工程有限公司 |
长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用
|
EP2573111A1
(en)
|
2006-04-20 |
2013-03-27 |
Amgen Inc. |
GLP-1 compounds
|
ATE444741T1
(de)
|
2006-05-10 |
2009-10-15 |
Biocompatibles Uk Ltd |
Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
|
AU2007267833B2
(en)
|
2006-05-26 |
2012-07-26 |
Amylin Pharmaceuticals, Llc |
Composition and methods for treatment of congestive heart failure
|
AU2007258609B2
(en)
|
2006-06-07 |
2013-01-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AR061930A1
(es)
*
|
2006-07-18 |
2008-10-01 |
Centocor Inc |
Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
|
EP2046826B1
(en)
|
2006-07-24 |
2011-09-14 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
CL2007002502A1
(es)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
|
US8552158B2
(en)
|
2006-08-31 |
2013-10-08 |
Hoffmann-La Roche Inc. |
Method for the production of insulin-like growth factor-1
|
CA2663047A1
(en)
*
|
2006-09-06 |
2008-03-13 |
Phase Bioscience, Inc. |
Therapeutic elastin-like polypeptide (elp) fusion proteins
|
PE20080840A1
(es)
*
|
2006-09-13 |
2008-08-27 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
EP1975176A1
(en)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Novel glp-1 fusion peptides, their production and use
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
MX2010000979A
(es)
|
2007-07-25 |
2010-03-26 |
Alexion Pharma Inc |
Metodos y composiciones para tratar enfermedad autoinmune.
|
WO2009020802A2
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
CN101842386A
(zh)
*
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
JP5591701B2
(ja)
|
2007-09-21 |
2014-09-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
|
JP2011503000A
(ja)
*
|
2007-11-02 |
2011-01-27 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
半合成GLP−1ペプチド−Fc融合コンストラクト、その方法及び使用
|
US20110020345A1
(en)
|
2008-03-31 |
2011-01-27 |
Christopher Herring |
Drug fusions and conjugates
|
BRPI0911266A2
(pt)
*
|
2008-04-03 |
2015-09-29 |
Hoffmann La Roche |
ensaio de fator de crescimento similar à insulina peguilado
|
CN101328221B
(zh)
*
|
2008-04-14 |
2011-03-23 |
中国药科大学 |
一种降糖多肽融合蛋白及其衍生物的结构及用途
|
EP3412300A1
(en)
|
2008-06-27 |
2018-12-12 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
RU2483081C2
(ru)
|
2008-07-23 |
2013-05-27 |
Ханми Сайенс Ко.,Лтд.,Kr |
Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
|
KR20110039348A
(ko)
|
2008-08-06 |
2011-04-15 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
|
US20100075897A1
(en)
*
|
2008-09-23 |
2010-03-25 |
Jinan University |
Method for sustainedly releasing bioactive peptides and application thereof
|
US8921314B2
(en)
|
2008-10-15 |
2014-12-30 |
Angiochem, Inc. |
Conjugates of GLP-1 agonists and uses thereof
|
EP2370471B1
(en)
|
2008-12-05 |
2017-02-22 |
Angiochem Inc. |
Neurotensin conjugate and uses thereof
|
AU2009324037B2
(en)
|
2008-12-05 |
2015-07-30 |
Glaxo Group Limited |
Methods for selecting protease resistant polypeptides
|
SI2373681T1
(sl)
|
2008-12-10 |
2017-05-31 |
Glaxosmithkline Llc Corporation Service Company |
Farmacevtski sestavki albiglutida
|
AU2010207725B2
(en)
|
2009-01-22 |
2015-06-11 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
JP5936112B2
(ja)
|
2009-02-11 |
2016-06-15 |
アルブミディクス アクティーゼルスカブ |
アルブミン変異体及び複合体
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
BRPI1013588A2
(pt)
|
2009-03-27 |
2016-04-19 |
Glaxo Group Ltd |
composição
|
US9173891B2
(en)
|
2009-04-20 |
2015-11-03 |
Angiochem, Inc. |
Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
|
IN2012DN00248A
(es)
|
2009-07-02 |
2015-05-01 |
Angiochem Inc |
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
CA2804755C
(en)
*
|
2009-08-14 |
2018-06-05 |
Phasebio Pharmaceuticals, Inc. |
Modified vasoactive intestinal peptides
|
CN101993485B
(zh)
*
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
CN101993496B
(zh)
*
|
2009-08-20 |
2013-06-05 |
重庆富进生物医药有限公司 |
双重调节血糖血脂融合蛋白及其制法和用途
|
SG10201406063XA
(en)
|
2009-09-30 |
2014-11-27 |
Glaxo Group Ltd |
Drug fusions and conjugates with extended half life
|
KR101229610B1
(ko)
*
|
2009-10-09 |
2013-02-05 |
한남대학교 산학협력단 |
Glp-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
|
US8697648B2
(en)
|
2009-10-20 |
2014-04-15 |
Georgia State University Research Foundation, Inc. |
Protein agent for diabetes treatment and β cell imaging
|
RU2607374C2
(ru)
|
2009-10-30 |
2017-01-10 |
Новозаймс Байофарма Дк А/С |
Варианты альбумина
|
CN102070717B
(zh)
*
|
2009-11-19 |
2013-04-10 |
东莞太力生物工程有限公司 |
融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物
|
EP2826489A1
(en)
|
2009-12-08 |
2015-01-21 |
Teva Pharmaceutical Industries, Ltd. |
BChE albumin fusions for the treatment of cocaine abuse
|
RU2012134974A
(ru)
|
2010-01-22 |
2014-02-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированное соединение гормона роста
|
WO2011089255A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US9981017B2
(en)
|
2010-04-02 |
2018-05-29 |
Hanmi Science Co., Ltd. |
Insulin conjugate using an immunoglobulin fragment
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CN101875700B
(zh)
*
|
2010-04-09 |
2012-09-26 |
无锡和邦生物科技有限公司 |
一种增加促胰岛素分泌肽融合蛋白生物活性的方法
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
KR20130093470A
(ko)
|
2010-04-30 |
2013-08-22 |
가부시키가이샤산와카가쿠켄큐쇼 |
생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
WO2011153642A1
(en)
*
|
2010-06-10 |
2011-12-15 |
Angiochem Inc. |
Leptin and leptin analog conjugates and fusion proteins and uses thereof
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
US9234023B2
(en)
*
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
JP2013530993A
(ja)
|
2010-07-02 |
2013-08-01 |
アンジオケム インコーポレーテッド |
治療用コンジュゲートのための短く且つd−アミノ酸を含有するポリペプチドおよびその使用
|
CN102311501A
(zh)
*
|
2010-07-08 |
2012-01-11 |
天津药物研究院 |
含有glp-1或其类似物的融合蛋白、制备方法及其应用
|
CN101906158B
(zh)
*
|
2010-07-14 |
2013-10-23 |
中国药科大学 |
一种聚乙二醇化降糖多肽及其制法和用途
|
KR101382593B1
(ko)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
|
CN102532323B
(zh)
*
|
2010-12-09 |
2014-07-23 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
EP3326620B1
(en)
|
2010-12-16 |
2020-03-04 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
|
CN102533655A
(zh)
*
|
2010-12-21 |
2012-07-04 |
青岛黄海制药有限责任公司 |
高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
|
US9266939B2
(en)
|
2010-12-27 |
2016-02-23 |
Alexion Pharmaceuticals, Inc. |
Compositions comprising natriuretic peptides and methods of use thereof
|
WO2012097333A2
(en)
|
2011-01-14 |
2012-07-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
JP5948683B2
(ja)
|
2011-02-28 |
2016-07-06 |
国立研究開発法人国立循環器病研究センター |
悪性腫瘍転移抑制用医薬
|
CN103732628B
(zh)
|
2011-03-03 |
2017-06-23 |
酵活有限公司 |
多价杂多聚体骨架设计和构建体
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
CA2832811A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
US9561262B2
(en)
|
2011-06-06 |
2017-02-07 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
ES2746052T3
(es)
|
2011-06-28 |
2020-03-04 |
Inhibrx Lp |
Polipéptidos de fusión de serpina y métodos de uso de los mismos
|
AU2012275295B2
(en)
|
2011-06-28 |
2016-11-10 |
Inhibrx, Lp |
WAP domain fusion polypeptides and methods of use thereof
|
EP2726502A1
(en)
|
2011-07-01 |
2014-05-07 |
Bayer Intellectual Property GmbH |
Relaxin fusion polypeptides and uses thereof
|
CA2840944A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
EP2745846A4
(en)
|
2011-08-19 |
2015-03-18 |
Nat Cerebral & Cardiovascular Ct |
MEDICAMENT FOR PREVENTING THE ABSORPTION OF SPICY TUMORS WITH A COMBINATION OF NATRIURETIC PEPTIDE RECEPTOR GC-A AGONISTS AND GC-B AGONISTS
|
CN103765213B
(zh)
*
|
2011-08-25 |
2016-08-17 |
美迪恩斯生命科技株式会社 |
胰高血糖素样肽-1的测定法及其中使用的试剂盒
|
JP6126097B2
(ja)
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー/エス |
Glp−1誘導体
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
WO2013083826A2
(en)
|
2011-12-09 |
2013-06-13 |
Novo Nordisk A/S |
Glp-1 agonists
|
KR101895047B1
(ko)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
|
EP2807266B1
(en)
|
2012-01-26 |
2020-01-15 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) polypeptides
|
AR090281A1
(es)
|
2012-03-08 |
2014-10-29 |
Hanmi Science Co Ltd |
Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
|
ES2664328T3
(es)
|
2012-03-16 |
2018-04-19 |
Albumedix A/S |
Variantes de albúmina
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
EP4324475A1
(en)
|
2012-03-22 |
2024-02-21 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
AU2013250711A1
(en)
|
2012-04-19 |
2014-11-27 |
Opko Biologics Ltd. |
Long-acting oxyntomodulin variants and methods of producing same
|
CN104411321A
(zh)
|
2012-05-16 |
2015-03-11 |
葛兰素集团有限公司 |
用于口服施用的加载有多肽的聚(辛基氰基丙烯酸酯)纳米颗粒
|
DK2849567T3
(da)
|
2012-05-17 |
2022-06-20 |
Extend Biosciences Inc |
Bærestoffer til forbedret lægemiddeladministration
|
CN104302772B
(zh)
*
|
2012-05-18 |
2017-11-10 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
SI2859015T1
(sl)
*
|
2012-06-08 |
2018-12-31 |
Alkermes Pharma Ireland Limited |
Ligandi, modificirani s cirkularno permutacijo, kot agonisti in antagonisti
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
AR094821A1
(es)
*
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
AR092862A1
(es)
*
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
US20140128326A1
(en)
|
2012-11-08 |
2014-05-08 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
SG10201610223PA
(en)
|
2012-11-20 |
2017-02-27 |
Opko Biolog Ltd |
Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
UA116553C2
(uk)
|
2012-12-21 |
2018-04-10 |
Санофі |
Пептидна сполука - агоніст рецептора glp-1 i glp
|
EP2945703A4
(en)
|
2013-01-15 |
2016-08-31 |
Teva Pharma |
ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
EP2981282B1
(en)
|
2013-04-05 |
2020-11-04 |
Novo Nordisk Health Care AG |
Growth hormone compound formulation
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
CN104277112B
(zh)
|
2013-07-04 |
2018-01-26 |
嘉和生物药业有限公司 |
长效降血糖融合蛋白
|
CN113527512A
(zh)
|
2013-07-31 |
2021-10-22 |
美国安进公司 |
生长分化因子15(gdf-15)构建体
|
CN103408669B
(zh)
*
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
Glp-1类似物融合蛋白,及其制备方法和用途
|
CN104371019B
(zh)
|
2013-08-13 |
2019-09-10 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
|
WO2015022420A1
(en)
*
|
2013-08-16 |
2015-02-19 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
CN105934252B
(zh)
|
2013-10-10 |
2020-11-10 |
贝思以色列女会吏医学中心公司 |
Tm4sf1结合蛋白及其使用方法
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
CA2941958A1
(en)
*
|
2013-12-10 |
2015-06-18 |
F. Hoffmann-La Roche Ag |
Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
AU2015242657B2
(en)
*
|
2014-03-31 |
2020-05-21 |
Hanmi Pharm. Co., Ltd. |
Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
NO2776305T3
(es)
|
2014-04-23 |
2018-01-27 |
|
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
CA2947982C
(en)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
CN104558198A
(zh)
*
|
2014-07-25 |
2015-04-29 |
成都贝爱特生物科技有限公司 |
GLP-1类似物和amylin类似物的融合蛋白制备及其用途
|
CN104257696B
(zh)
*
|
2014-09-04 |
2017-08-25 |
西安国誉生物科技有限公司 |
一种降糖稳糖酵母菌粉及其制备方法和应用
|
US10968266B2
(en)
|
2014-09-05 |
2021-04-06 |
University Of Copenhagen |
GIP peptide analogues
|
EP3204408B1
(en)
*
|
2014-10-10 |
2020-05-06 |
Novo Nordisk A/S |
Stable glp-1 based glp-1/glucagon receptor co-agonists
|
CN104327187B
(zh)
*
|
2014-10-11 |
2018-06-08 |
上海兴迪金生物技术有限公司 |
一种重组人GLP-1-Fc融合蛋白
|
JP6946182B2
(ja)
|
2014-10-22 |
2021-10-06 |
エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc |
治療用ビタミンdコンジュゲート
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
KR20180004094A
(ko)
*
|
2014-11-06 |
2018-01-10 |
칠드런스 내셔널 메디컬 센터 |
암 및 자가면역 질환을 위한 면역 요법
|
AU2015357551B2
(en)
|
2014-12-05 |
2021-02-25 |
Alexion Pharmaceuticals, Inc. |
Treating seizure with recombinant alkaline phosphatase
|
NZ732073A
(en)
*
|
2014-12-08 |
2019-04-26 |
1Globe Biomedical Co Ltd |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
CA2973883A1
(en)
|
2015-01-28 |
2016-08-04 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
US10688156B2
(en)
|
2015-02-09 |
2020-06-23 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating muscle disease and disorders
|
WO2016127887A1
(zh)
|
2015-02-11 |
2016-08-18 |
杭州鸿运华宁生物医药工程有限公司 |
一种药用glp-1r抗体融合蛋白的稳定溶液制剂
|
EP3277302A4
(en)
*
|
2015-04-01 |
2018-12-05 |
The Scripps Research Institute |
Methods and compositions related to gpcr agonist polypeptides
|
MY188430A
(en)
|
2015-04-10 |
2021-12-08 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
AR105616A1
(es)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
DK3307326T3
(da)
|
2015-06-15 |
2020-10-19 |
Angiochem Inc |
Fremgangsmåder til behandling af leptomeningeal karcinomatose
|
EP3310347B1
(en)
|
2015-06-19 |
2021-08-04 |
OPKO Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
EP3337894A1
(en)
|
2015-08-17 |
2018-06-27 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of alkaline phosphatases
|
MX2018001825A
(es)
|
2015-08-20 |
2018-05-07 |
Albumedix As |
Variantes y conjugados de albumina.
|
WO2017041001A2
(en)
|
2015-09-04 |
2017-03-09 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
|
EP3368062A4
(en)
|
2015-10-30 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
|
CN105367664B
(zh)
*
|
2015-11-04 |
2019-09-20 |
成都贝爱特生物科技有限公司 |
激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
|
EP3377520A4
(en)
*
|
2015-11-16 |
2019-11-06 |
Ubiprotein, Corp. |
METHOD FOR EXTENDING THE HALF-LIFE OF A PROTEIN
|
PT3380495T
(pt)
|
2015-11-24 |
2021-08-19 |
Transfert Plus Sec |
Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
|
US11065306B2
(en)
|
2016-03-08 |
2021-07-20 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
MX2018011833A
(es)
|
2016-04-01 |
2019-02-13 |
Alexion Pharma Inc |
Tratamiento para la debilidad muscular con fosfatasas alcalinas.
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
CN109071634A
(zh)
|
2016-04-26 |
2018-12-21 |
R.P.谢勒技术有限责任公司 |
抗体偶联物及其制备和使用方法
|
WO2017214130A1
(en)
|
2016-06-06 |
2017-12-14 |
Alexion Pharmaceuticals, Inc. |
Metal impact on manufacturing of alkaline phosphatases
|
HUE064463T2
(hu)
|
2016-07-11 |
2024-03-28 |
Opko Biologics Ltd |
Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
|
CN106046176B
(zh)
*
|
2016-08-16 |
2019-09-10 |
中国药科大学 |
一种高活性长效降糖融合蛋白及其制备方法与医药用途
|
US11116821B2
(en)
|
2016-08-18 |
2021-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|
WO2018045872A1
(zh)
*
|
2016-09-06 |
2018-03-15 |
中国药科大学 |
一种多肽及其用途
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
CN106279400A
(zh)
*
|
2016-09-06 |
2017-01-04 |
中国药科大学 |
P8降糖肽的设计及其用途
|
CN110582302A
(zh)
*
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和/或蛋白有效负载递送的组合物和方法
|
CN106519016A
(zh)
*
|
2016-12-20 |
2017-03-22 |
中国药科大学 |
降糖调脂肽——Progly肽的设计及其用途
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
CN110225924B
(zh)
*
|
2017-01-25 |
2024-04-02 |
免疫医疗有限公司 |
松弛素融合多肽及其用途
|
CA3057502A1
(en)
|
2017-03-31 |
2018-10-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia (hpp) in adults and adolescents
|
CN108727486A
(zh)
*
|
2017-04-24 |
2018-11-02 |
舒泰神(北京)生物制药股份有限公司 |
长效神经生长因子、制备方法及其组合物
|
AU2018273406A1
(en)
|
2017-05-24 |
2020-01-16 |
Transfert Plus, S.E.C. |
Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
|
JP2020521784A
(ja)
|
2017-05-31 |
2020-07-27 |
ユニバーシティ オブ コペンハーゲン |
長時間作用性gipペプチド類似体
|
CN111050750A
(zh)
|
2017-08-24 |
2020-04-21 |
诺沃挪第克公司 |
Glp-1组合物及其用途
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
CA3082625A1
(en)
|
2017-11-21 |
2019-05-31 |
Eli Lilly And Company |
Methods of using and compositions containing dulaglutide
|
CN109836503B
(zh)
*
|
2017-11-24 |
2022-09-16 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多重活性蛋白
|
CN109836504B
(zh)
*
|
2017-11-24 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
CN109929806B
(zh)
|
2017-12-19 |
2020-05-08 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
CN110028587B
(zh)
*
|
2018-01-11 |
2021-10-08 |
安源医药科技(上海)有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
CN110092835A
(zh)
*
|
2018-01-30 |
2019-08-06 |
上海惠盾生物技术有限公司 |
一种glp-1类似物-col3a1融合蛋白
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
JP2021519590A
(ja)
|
2018-03-30 |
2021-08-12 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
糖タンパク質の製造
|
PL3774862T3
(pl)
|
2018-04-05 |
2022-10-03 |
Sun Pharmaceutical Industries Limited |
Nowe analogi glp-1
|
WO2019199685A1
(en)
|
2018-04-09 |
2019-10-17 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
CN110964116A
(zh)
*
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
CR20210193A
(es)
*
|
2018-10-22 |
2021-06-15 |
Janssen Pharmaceutica Nv |
Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
|
US20220298218A1
(en)
|
2018-12-03 |
2022-09-22 |
Antag Therapeutics Aps |
Modified GIP Peptide Analogues
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
TW202024134A
(zh)
|
2018-12-21 |
2020-07-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
雙特異性蛋白
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
CN110151980B
(zh)
*
|
2019-06-30 |
2022-12-09 |
中国药科大学 |
Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
|
CN115135305A
(zh)
|
2020-02-18 |
2022-09-30 |
诺和诺德股份有限公司 |
药物制剂
|
CA3171988A1
(en)
|
2020-02-22 |
2021-08-26 |
Jcr Pharmaceuticals Co., Ltd. |
Human transferrin receptor binding peptide
|
CN115925995A
(zh)
*
|
2020-09-30 |
2023-04-07 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
IL307225A
(en)
|
2021-03-22 |
2023-11-01 |
Peptiaid Inc |
A peptide and a preparation containing a peptide
|
TW202305012A
(zh)
|
2021-03-22 |
2023-02-01 |
日商肽夢想股份有限公司 |
c-Met 蛋白質結合肽複合物
|
CN113150172B
(zh)
*
|
2021-04-28 |
2023-09-22 |
中国药科大学 |
Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
|
CA3222510A1
(en)
|
2021-06-18 |
2022-12-22 |
Peptidream Inc. |
Ghr-binding pending peptide and composition comprising same
|
WO2023022234A1
(ja)
|
2021-08-19 |
2023-02-23 |
ペプチドリーム株式会社 |
ヒトトランスフェリンレセプター結合ペプチド
|
JPWO2023026994A1
(es)
|
2021-08-21 |
2023-03-02 |
|
|
CA3229962A1
(en)
|
2021-08-24 |
2023-03-02 |
Peptidream Inc. |
Human transferrin receptor-binding antibody-peptide conjugate
|
CN113801853B
(zh)
*
|
2021-11-19 |
2022-03-15 |
山东兴瑞生物科技有限公司 |
Exendin-4融合基因修饰的MSC及其应用
|
EP4337244A1
(en)
*
|
2022-03-25 |
2024-03-20 |
Beijing QL Biopharmaceutical Co., Ltd. |
Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
|
CN116848243B
(zh)
*
|
2022-03-30 |
2024-03-19 |
北京质肽生物医药科技有限公司 |
多肽缀合物的液体药物组合物和其使用方法
|
CN114774496B
(zh)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高密度发酵制备glp-1类似物的方法
|